Home » Stocks » KROS

Keros Therapeutics, Inc. (KROS)

Stock Price: $71.59 USD -3.69 (-4.90%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 1.66B
Revenue (ttm) 2.50M
Net Income (ttm) n/a
Shares Out 20.18M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $71.59
Previous Close $75.28
Change ($) -3.69
Change (%) -4.90%
Day's Open 75.02
Day's Range 71.29 - 75.02
Day's Volume 145,014
52-Week Range 20.08 - 82.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 month ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CAR, BH, GSKY, GTHX, ORGO, REYN, WTRH
GlobeNewsWire - 1 month ago

LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and comm...

GlobeNewsWire - 2 months ago

LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev...

Seeking Alpha - 3 months ago

Following an active September, two IPOs are scheduled to raise $200 million in the week ahead.

Other stocks mentioned: FUBO
GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and c...

GlobeNewsWire - 4 months ago

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, ...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and co...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, d...

GlobeNewsWire - 5 months ago

LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, d...

GlobeNewsWire - 6 months ago

LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, de...

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, IMRA, PCVX, RNA, RPTX, XBI, ZNTL
Zacks Investment Research - 6 months ago

Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and co...

GlobeNewsWire - 7 months ago

LEXINGTON, Mass., May 22, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and com...

Benzinga - 8 months ago

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.

The Motley Fool - 8 months ago

These companies just raised significant cash to advance promising drug pipelines.

Other stocks mentioned: ZNTL
GuruFocus - 8 months ago

The Covid-19 pandemic has waylaid what was supposed to be an active year in biotech initial public offerings.

GlobeNewsWire - 9 months ago

LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and c...

Seeking Alpha - 9 months ago

Keros Therapeutics finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility.

About KROS

Keros Therapeutics, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing sm... [Read more...]

Industry
Biotechnology
IPO Date
Apr 8, 2020
CEO
Dr. Jasbir Seehra
Employees
32
Stock Exchange
NASDAQ
Ticker Symbol
KROS
Full Company Profile

Financial Performance

In 2019, KROS's revenue was $10.00 million, a change of 0.00% compared to the previous year's $10.00 million. Losses were -$14.14 million, 502.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is 86.25, which is an increase of 20.48% from the latest price.

Price Target
$86.25
(20.48% upside)
Analyst Consensus: Buy